IGF-1 LR3 the science.

Native IGF-1 is a 70-amino-acid peptide that circulates bound to IGF-binding proteins (IGFBPs), which regulate how much is free and active. Long R3 IGF-1 is a recombinant analog carrying two changes: an arginine substitution at position 3 (the “R3”) that lowers IGFBP affinity, and a 13-amino-acid N-terminal extension (the “Long”), giving an 83-residue peptide. Together these make it longer-acting and more potent in culture.

Because of that potency, IGF-1 LR3 is a common reagent in cell-biology and physiology laboratories. It is supplied here strictly as a research material.

IGF-1 LR3 research focuses on the IGF-1 signaling axis:

• IGF-1 receptor (IGF-1R) — activation of this tyrosine-kinase receptor drives downstream growth signaling.
• PI3K/Akt and MAPK — the canonical pathways studied for cell survival, proliferation, and differentiation.
• Reduced IGFBP binding — the defining feature investigated as the reason for the analog’s sustained activity in culture.

IGF-1 LR3 appears across in vitro and animal research as a tool for stimulating IGF-1 signaling:

• Myogenic cell models. Studies have used long-R3-IGF-I to stimulate proliferation and differentiation of muscle (myoblast) cell lines, often alongside IGF-binding-protein experiments.
• Cell-culture supplementation. It is widely used to support cell growth and as a comparator for studying IGF-1R signaling and IGFBP regulation.

These are laboratory observations. They do not establish human safety, dosing, or benefit.

The IGF-1 LR3 evidence base is in vitro and preclinical; it is used as a research growth factor rather than studied as a human therapeutic. No human safety, dosing, or efficacy is established here. IGF-1 LR3 is supplied strictly as a research material — for research use only, not for human or veterinary use.